Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.58 |
| ▸ | LTA4H | P09960 | 6/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | BAX | Q07812 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.45 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.45 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.45 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5534679 | 0.88 | FFAR1 (0.55) | FFAR1LTA4HTSHRSRD5A2FFAR4 | |
| SCHEMBL19322270 | 0.86 | LTA4H (0.67) | FFAR1LTA4HTSHRSRD5A2FFAR4 | |
| SCHEMBL5535812 | 0.86 | FFAR1 (0.53) | FFAR1LTA4HTSHRSRD5A2FFAR4 | |
| SCHEMBL5539299 | 0.84 | FFAR1 (0.51) | FFAR1LTA4HTSHRSRD5A2FFAR4 | |
| SCHEMBL28724005 | 0.84 | FFAR1 (0.64) | FFAR1LTA4HTSHRSRD5A2FFAR4 | |
| SCHEMBL28297211 | 0.82 | LTA4H (0.61) | FFAR1LTA4HTSHRSRD5A2NR1H2 | |
| SCHEMBL2201304 | 0.82 | FFAR1 (0.62) | FFAR1LTA4HTSHRSRD5A2FFAR4 | |
| SCHEMBL694932 | 0.82 | LTA4H (0.61) | FFAR1LTA4HTSHRSRD5A2NR1H2 | |
| SCHEMBL19322272 | 0.82 | FFAR1 (0.62) | FFAR1LTA4HTSHRSRD5A2FFAR4 | |
| SCHEMBL5540055 | 0.82 | FFAR1 (0.50) | FFAR1LTA4HTSHRFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0960108-B1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2004-10-27 | — | — | EP | claimed |
| US-6329400-B1 | INHIBITION OR ANTAGONISM OF MATRIX METALLOPROTEASES, AND/OR TUMOR NECROSIS FACTOR-ALPHA; EXTRACELLULAR MATRIX DEGRADATION, INHIBITION OF SHEDDING OF CELL SURFACE PROTEIN ECTODOMAINS AND CD23 PROTEOLYSIS | GLAXO WELLCOME INC. | 2001-12-11 | — | — | US | claimed |
| US-6194451-B1 | PREVENT RELEASE TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2001-02-27 | — | — | US | claimed |
| US-6172064-B1 | METALLOPROTEASE INHIBITOR; ANTIARTHRITIC AGENTS, ANTIDIABETIC AGENTS; ANTITUMOR AGENTS | GLAXO WELLCOME INC. | 2001-01-09 | — | — | US | claimed |
| WO-2000012082-A1 | FORMAMIDE COMPOUNDS AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | claimed |
| EP-0960108-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.p.A. (IT) | 1999-12-01 | — | — | EP | claimed |
| WO-1998033788-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1998-08-06 | — | — | WO | claimed |
| US-12030970-B2 | Curable composition and stereolithographic resin composition comprising same | KURARAY CO., LTD. (JP) | 2024-07-09 | — | — | US | disclosed |
| US-11981763-B2 | Resin composition for stereolithographic modeling | KURARAY NORITAKE DENTAL INC. (JP) | 2024-05-14 | — | — | US | disclosed |
| EP-3900693-B1 | USE OF A RESIN COMPOSITION | KURARAY NORITAKE DENTAL INC (JP) | 2024-03-20 | — | — | EP | disclosed |
| US-11814454-B2 | Curable composition, and resin composition for stereolithography prepared therefrom | KURARAY CO., LTD. (JP) | 2023-11-14 | — | — | US | disclosed |
| EP-4268792-A1 | ADHESIVE COMPOSITION FOR PHOTOFABRICATION ARTICLES | Kuraray Noritake Dental Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023182514-A1 | ADHESIVE COMPOSITION FOR STEREOLITHOGRAPHIC ARTICLE AND NON-STEREOLITHOGRAPHIC ARTICLE | クラレノリタケデンタル株式会社 | 2023-09-28 | — | — | WO | disclosed |
| CN-1043886-C | Substituted pyrimidines, their production and use as pesticides and fungicides | HOECHST AG (DE) | 1999-06-30 | — | — | CN | disclosed |
| EP-0922050-A1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1999-06-16 | — | — | EP | disclosed |
| WO-1998033788-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1998-08-06 | — | — | WO | disclosed |
| US-5750510-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1997042205-A1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1997-11-13 | — | — | WO | disclosed |
| CN-1076692-A | Substituted pyrimidines, their production and use as pesticides and fungicides | HOECHST AG (DE) | 1993-09-29 | — | — | CN | disclosed |
| EP-0485026-A2 | Antimanic phenoxymethylene bisphosphonate derivatives | MERCK SHARP & DOHME LTD. (GB) | 1992-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814454-B2 | Curable composition, and resin composition for stereolithography prepared therefrom | WASF2, COPE, ARCN1 | FFAR1 493/4885LTA4H 1081/4885TSHR 4743/4885 |
| US-12030970-B2 | Curable composition and stereolithographic resin composition comprising same | ARL1, ASH2L, VCL | FFAR1 1616/4885LTA4H 640/4885TSHR 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.